Title
Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone
Date Issued
01 January 2022
Access level
open access
Resource Type
journal article
Author(s)
Stony Brook University
Publisher(s)
Elsevier Ltd
Abstract
Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.
Volume
27
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Ciencias médicas, Ciencias de la salud
Subjects
Scopus EID
2-s2.0-85125251191
Source
IDCases
ISSN of the container
22142509
Sponsor(s)
Dr. Marcos does not have any disclosures. Dr. Kirkman does not have any disclosures. Annie Leung does not have any disclosures. Dr. Wormser reports receiving research grants from the Institute for Systems Biology and Pfizer, Inc. He has been an expert witness in malpractice cases involving babesiosis; and is an unpaid board member of the non-profit American Lyme Disease Foundation.
Sources of information:
Directorio de Producción Científica
Scopus